Compare PTGX & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | TWST |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.2B |
| IPO Year | 2016 | 2018 |
| Metric | PTGX | TWST |
|---|---|---|
| Price | $139.52 | $138.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $178.21 | $163.67 |
| AVG Volume (30 Days) | 722.9K | ★ 2.7M |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 2.35 | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $1,077.07 | $21.17 |
| Revenue Next Year | N/A | $20.24 |
| P/E Ratio | $59.42 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $74.03 | $23.30 |
| 52 Week High | $160.81 | $219.71 |
| Indicator | PTGX | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 42.82 |
| Support Level | $135.10 | $122.05 |
| Resistance Level | $142.20 | $155.44 |
| Average True Range (ATR) | 6.12 | 16.12 |
| MACD | 0.22 | -3.80 |
| Stochastic Oscillator | 49.12 | 7.71 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.